PPARG and lipodystrophy: We applied our reprogramming protocol to a panel of cells derived from patients with monogenic insulin resistance either attributable to an insulin signalling defect (INSR, PIK3R1), to primary lipodystrophy (BSCL2, PCYT1A, PPARG or LMNA), or forming part of a more complex, pleiotropic syndrome (ALMS1, WRN, BLM, NSMCE2).